Pull to refresh
Logo
What Changed
Following Why Sign Up
Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201

Lumen Bio reports positive Phase 2 results for oral C. diff drug LMN-201

New Capabilities

LMN-201 cut recurrence to 9.1% versus 55.6% with placebo; Lumen wants a partner for a larger Phase 3

October 21st, 2026: Phase 2 Part B results reported

Overview

Updated Oct 26

Lumen Bioscience said on October 21 that its oral biologic LMN-201 cured a C. difficile infection and kept it from returning in 83.3% of patients in a placebo-controlled Phase 2 trial, against 36.4% on placebo. Recurrence was 9.1% with the drug and 55.6% with placebo in the 23-patient Part B group.

Carl Mason, Lumen's head of clinical research, was scheduled to give the late-breaking oral at IDWeek in Washington on October 24. No new data from that session have been published. Lumen is still looking for a partner to pay for a larger Phase 3 trial, and a registry entry lists the RePreve study running to December 2027.

Why it matters

If LMN-201 works at scale, it could break the cycle of recurrent C. diff infections that sends patients back to hospitals each year.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

83.3%
Global cure with LMN-201 (Part B)
Initial cure plus no recurrence; 10 of 12 patients versus 4 of 11 on placebo.
9.1%
C. diff recurrence with LMN-201
Compared with 55.6% for placebo in the Part B cohort.
8.75
Odds ratio for global cure
Statistically significant under the prespecified Bayesian analysis plan.
23
Patients in randomized Part B cohort
Small sample; independent observers caution the effect size is uncertain.

Voices

Curated perspectives — historical figures and your fellow readers.

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Carl Mason, MD
Carl Mason, MD
Head of Clinical Research, Lumen Bioscience
Was scheduled to present the RePreve Part B results in a late-breaking oral at IDWeek on October 24, 2026; no account of the session's content has been published
 Kole Krieger
Kole Krieger
Senior Vice President of Business Development, Lumen Bioscience
Leading commercial strategy for LMN-201

Organizations Involved

Lumen Bioscience
Lumen Bioscience
Biotechnology company
Phase 2 Part B results reported; seeking a partner to fund a larger Phase 3

Seattle biotech developing oral protein therapeutics grown in engineered spirulina.

Timeline

December 2021 October 2026

7 events Latest: October 21st, 2026 · 3 weeks ago
Tap a bar to jump to that date

  1. Phase 2 Part B results reported

    Latest Clinical Trial

    Global cure 83.3% with LMN-201 versus 36.4% placebo; recurrence 9.1% versus 55.6%. The company said the data would be featured in a late-breaking oral at IDWeek on October 24.

  2. Lumen seeks partner to fund Phase 3

    Corporate

    With positive Phase 2 data in hand, Lumen said it wants a well-funded partner to help pay for a larger Phase 3 study of LMN-201.

  3. Lumen publishes the design behind LMN-201's potency

    Research

    A Lumen paper says the three antibodies in LMN-201 bind separate sites on C. difficile toxin B and work together, making the mix 300- to 3,000-fold more potent than bezlotoxumab against common toxin types. The cocktail also carries an enzyme that kills the bacterium.

  4. Trial timelines extended

    Clinical Trial

    Registry shows primary completion moved to June 2027 and study end to December 2027.

  5. Lumen expands board and leadership

    Corporate

    New funding and executives support late-stage clinical programs and commercial readiness for LMN-201.

  6. Sentinel cohort hits 100% initial cure

    Clinical Trial

    21 of 21 RePreve sentinel patients achieved initial clinical cure; Lumen has reported a sustained cure rate at four weeks above 90%.

  7. LMN-201 preclinical data posted

    Research

    bioRxiv preprint describes the spirulina platform, synthetic avidity design, and rodent challenge results.

Scenarios

1

LMN-201 moves into a pivotal Phase 3 trial

Likely Resolves by Q2 2028

Discussed by: Lumen Bioscience; clinical observers following the RePreve program

With positive Part B data, Lumen is expected to launch the larger pivotal cohort described under the RePreve protocol. The company has said it is gearing up for late-stage work and commercial readiness. A registry entry notes the study currently runs to late 2027.

2

Pivotal cohort fails to confirm the recurrence reduction

Possible Resolves by End of 2028

Discussed by: pharmacally.com and independent clinicians citing the 23-patient sample

The Part B result rests on a small sample, and recurrence is a noisy endpoint. A larger pivotal cohort would test whether the effect holds under more typical enrollment, where the placebo rate may differ from the 55.6% observed here.

3

LMN-201 wins FDA approval as a first-in-class oral biologic

Uncertain Resolves by End of 2030

Discussed by: Industry analysts tracking oral biologic approvals

The full approval path, with a successful Phase 3 and a BLA filing, would make LMN-201 one of the first cocktail biologics delivered orally. Lumen would compete with IV bezlotoxumab and oral microbiome products like Vowst for the recurrence-prevention market.

4

Lumen signs a partner to fund the LMN-201 Phase 3

Possible Resolves by End of 2027

Discussed by: Lumen Bioscience, as reported by Citeline/Scrip

Lumen has said it wants a deep-pocketed partner to help finance a larger pivotal study of LMN-201. A deal would fund the cohort described under the RePreve protocol and move the program toward a filing.

Historical Context

2 moments from history that rhyme with this story — and how they unfolded.

2016

Bezlotoxumab (Zinplava, 2016)

FDA approved bezlotoxumab, an IV monoclonal antibody that neutralizes C. diff toxin B, to prevent recurrence in high-risk adults. Its Phase 3 MODIFY I and II trials enrolled over 1,500 patients and set the benchmark for immunotherapy in this disease.

Then

Approved as an add-on to standard antibiotics, marketed as Zinplava.

Now

Established that targeting toxins can prevent recurrence, but IV infusion limits where and how often it is used.

Why this matters now

LMN-201 is benchmarked directly against the MODIFY I/II results, aiming to match or beat them with an oral capsule instead of an infusion.

2023

Vowst (fecal microbiota spores, 2023)

FDA approved Vowst, an oral therapeutic made from purified fecal microbiota spores, for preventing recurrent C. diff after antibiotic treatment. It was the first oral microbiome drug cleared for this indication.

Then

Gave clinicians a pill-based option for recurrence prevention.

Now

Showed oral prevention is feasible; placebo recipients in its Phase 3 still had 38% to 46% eight-week recurrence rates.

Why this matters now

Vowst defined the oral C. diff prevention market LMN-201 wants to enter, and its high placebo recurrence rates underline the need LMN-201 targets.

Sources

(9)
+3
PR Newswire Pharmacally Lumen Bioscience AdisInsight bioRxiv Drug Discovery Trends Citeline/Scrip Lumen Bioscience Lumen Bioscience